Effect of insulin on the soluble receptor for advanced glycation end products (RAGE)

Diabetic Medicine

Volumn 30, Issue 6, 2013, Pages 702-709

  Lam, J K Y ^a   Wang, Y ^a   Shiu, S W M ^a   Wong, Y ^a   Betteridge, D J ^b   Tan, K C B ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; ILOMASTAT; INSULIN; ISOPROTEIN; MESSENGER RNA;

ADULT; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WESTERN BLOTTING;

ADULT; BIOLOGICAL MARKERS; CELL LINE; CELL MEMBRANE; CHINA; CROSS-SECTIONAL STUDIES; CULTURE MEDIA, CONDITIONED; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; PROTEIN ISOFORMS; PROTEOLYSIS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY; UP-REGULATION;

EID: 84878074857     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12166     Document Type: Article

References (25)

1. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 2011; 121: 43-55.
2. Vazzana N, Santilli F, Cuccurullo C, Davì G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009; 4: 389-401.
3. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-3727.
4. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-1580.
5. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009; 116: 621-637.
6. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009; 6: 7-14.
7. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011; 60: 2379-2385.
8. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH et al. Higher plasma soluble receptor for advanced glycation end product (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010; 59: 2027-2032.
9. Thomas MC, Söderlund J, Lehto M, Mäkinen VP, Moran JL, Cooper ME et al. FinnDiane Study Group Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia. 2011; 54: 2669-2677.
10. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005; 28: 2716-2721.
11. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008; 5: 190-197.
12. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109.
13. Grossin N, Wautier MP, Picot J, Stern DM, Wautier JL. Differential effect of plasma or erythrocyte AGE-ligands of RAGE on expression of transcripts for receptor isoforms. Diabetes Metab 2009; 35: 410-417.
14. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A 2007; 104: 19796-19801.
15. Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216: 192-198.
16. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73: 158-165.
17. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation end products in patients with type 1 diabetes. Clin Chem 2005; 51: 1749-1750.
18. Dettoraki A, Gil AP, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009; 22: 895-904.
19. Reis JS, Veloso CA, Volpe CM, Fernandes JS, Borges EA, Isoni CA et al. Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diab Vasc Dis Res 2012; 9: 309-314.
20. Skrha J Jr, Kalousová M, Svarcová J, Muravská A, Kvasnička J, Landová L et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120: 277-281.
21. Kalousova M, Hodkova M, Kazderova M, Fialová J, Tesar V, Dusilová-Sulková S et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411.
22. Tan KCB, Chow WS, Tso AWK, Xu A, Tse HF, Hoo RL et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end products in type 2 diabetes. Diabetologia 2007; 50: 1819-1825.
23. Tam HL, Shiu SWM, Wong Y, Chow WS, Betteridge DJ, Tan KCB. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-177.
24. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16: 2363-2372.
25. Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 2008; 370: 1-5.